Skip to main content
OpenTrials

Clinical trial condition

Lung Diseases, Obstructive

Explore clinical trials studying Lung Diseases, Obstructive. Study availability and eligibility vary by location and protocol.

7,959 public trials 737 recruiting studies
Refine in advanced search Browse all conditions

Lung Diseases, Obstructive trial results

Completed

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.40.11003 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
  • 1222.40.11001 Boehringer Ingelheim Investigational Site Clearwater, Florida, United States
  • 1222.40.11002 Boehringer Ingelheim Investigational Site Tampa, Florida, United States
  • 1222.40.49401 Boehringer Ingelheim Investigational Site Berlin, Germany
View Trial Details
Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040689

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.39.32003 Boehringer Ingelheim Investigational Site Genk, Belgium
  • 1222.39.32001 Boehringer Ingelheim Investigational Site Ghent, Belgium
  • 1222.39.32002 Boehringer Ingelheim Investigational Site Hasselt, Belgium
  • 1222.39.45001 Boehringer Ingelheim Investigational Site Hvidovre, Denmark
View all 15 locations
View Trial Details
Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

NCT00467740

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 1222.6.064 Arthur F. Gelb Medical Corporation, Lakewood Lakewood, California, United States
  • 1222.6.062 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
  • 1222.6.066 Allergy & Asthma Medical Group and Rsrch Ctr, APC San Diego, California, United States
  • 1222.6.069 Allergy Associates Medical Group San Diego, California, United States
View all 37 locations
View Trial Details
Completed

12 / 48 wk Pivotal PFT vs PBO in COPD II

NCT00782509

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.12.1227 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 1222.12.1218 Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
  • 1222.12.1226 Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
  • 1222.12.1214 Boehringer Ingelheim Investigational Site Waterbury, Connecticut, United States
View all 51 locations
View Trial Details
Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

NCT00824382

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.22.048 Boehringer Ingelheim Investigational Site Asahikawa, Hokkaido, Japan
  • 1222.22.044 Boehringer Ingelheim Investigational Site Bunkyo-ku, Tokyo, Japan
  • 1222.22.008 Boehringer Ingelheim Investigational Site Chiba, Chiba, Japan
  • 1222.22.002 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan
View all 48 locations
View Trial Details
Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

NCT01013753

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 1222.27.43002 Boehringer Ingelheim Investigational Site Linz, Austria
  • 1222.27.43004 Boehringer Ingelheim Investigational Site Schlüsslberg, Austria
  • 1222.27.43001 Boehringer Ingelheim Investigational Site Thalheim bei Wels, Austria
  • 1222.27.43003 Boehringer Ingelheim Investigational Site Vienna, Austria
View all 27 locations
View Trial Details
Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400

Conditions
Asthma, Bronchial Diseases, Chronic Disease, +11 more
Locations
  • 1222.5.03 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1222.5.07 Boehringer Ingelheim Investigational Site Lakewood, California, United States
  • 1222.5.14 Boehringer Ingelheim Investigational Site Denver, Colorado, United States
  • 1222.5.13 Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
View all 42 locations
View Trial Details
Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

NCT00793624

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.13.2401 Boehringer Ingelheim Investigational Site Capital Federal, Argentina
  • 1222.13.2403 Boehringer Ingelheim Investigational Site Capital Federal, Argentina
  • 1222.13.2402 Boehringer Ingelheim Investigational Site Mar del Plata, Argentina
  • 1222.13.2404 Boehringer Ingelheim Investigational Site Monte Grande, Argentina
View all 93 locations
View Trial Details
Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

NCT00796653

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.14.5004 Boehringer Ingelheim Investigational Site Capital Federal, Argentina
  • 1222.14.5003 Boehringer Ingelheim Investigational Site Mar del Plata, Argentina
  • 1222.14.5001 Boehringer Ingelheim Investigational Site Mendoza, Argentina
  • 1222.14.5002 Boehringer Ingelheim Investigational Site Quilmes, Argentina
View all 98 locations
View Trial Details

Related conditions